In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asthmatx Positive Panel Outcome Good Sign for Pulmonology Companies

Executive Summary

The FDA's Anesthesiology and Respiratory Device Panel delivered good news to the interventional pulmonology sector by issuing a positive recommendation for Asthmatx Inc.'s Alair Bronchial Thermoplasty System, a treatment for severe asthma. The positive news came nearly a year after the same panel voted not to recommend Emphasys Inc.'s lung airway valve as a treatment for emphysema.
Advertisement

Related Content

Pulmonary Device Companies Take It To The Streets - In Europe
Vertebral Compression Fracture Treatments Under Pressure
Asthmatx Following the Leaders In Defining Alair Sales Strategy
Tighter FDA Review Squeezing Device VCs
Emphysema Devices Search for Breathing Room
Emphysema: Elusive Target for Device Companies
Asthmatx Breathes Easier
Asthmatx Breathes Easier
Devices Fill The Lung Space
Devices Fill The Lung Space

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003212

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel